prelim report, page-25

G'day Dhukka,

Yes, some interesting points re marketing expenditures and product development expenditures. I guess the extent of these will progressively become clearer over the coming year.

An additional point that you bring to mind is the current market penetration. The total market for latent TB testing in CSTs designated markets is probably somewhere between 40m and 50m tests p.a. In 2008 FY the company achieved a $2m+ profit on sales of less than 1 million tests. That is less that 2% of the potential market. Lots of room to grow! And the evidence is that they are growing.

In the end, I can't say it any better than you have Dhukka:

What's not to like about this company?